Adults 45 to 100, any sex, with Knee Osteoarthritis or Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in WOMAC Pain (0-20 Scale)Primary· Baseline -> Week 4
The WOMAC Pain subscale measures self-reported knee pain severity during daily activities. The subscale consists of 5 items assessing pain during walking, stair climbing, nocturnal pain, pain at rest, and weight-bearing activities. Each item is scored 0-4 (0=none, 4=extreme), yielding a total Pain subscale score of 0-20. Higher scores indicate greater pain severity. Change scores were calculated as post-treatment minus baseline; negative values indicate improvement (reduced pain).
Group
Value
95% CI
Oxytocin
-0.14
± 2.92
Placebo
-0.65
± 3.03
Adverse events — posted to ClinicalTrials.gov
Time frame: During each 4-week treatment period (8 weeks total across both crossover periods).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Osteoarthritis (OA) represents a significant cause of disability worldwide and the knee is the most commonly affected joint. Oxytocin (OT) is a mediator of endogenous analgesia in animal and human studies. This proposal will test the efficacy and safety of self-administered intranasal OT over 4-weeks in older individuals relative to placebo (P) evaluating its effects on pain and function in aging and testing potential underlying neurobiological mechanisms.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
· EARLY_PHASE1
· recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte
· NA
· recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment
· NA
· recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis
· NA
· recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA
· NA
· recruiting
Other University of Florida trials
Trials by the same sponsor.
NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
· NA
· not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia
· NA
· suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl
· Phase 2, PHASE3
· not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
· Phase 1
· not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 23 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03878589.